PDF herunterladen
TumorDiagnostik & Therapie 2018; 39(03): 165-170
DOI: 10.1055/a-0574-5187
Schwerpunkt Ovarialkarzinom
© Georg Thieme Verlag KG Stuttgart · New York

Genetik und Prävention des Ovarialkarzinoms

Anna Jaeger
,
Linn Wölber
,
Katharina Prieske
,
Barbara Schmalfeldt
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. April 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Ein wesentlicher Risikofaktor für die Entwicklung eines Ovarialkarzinoms ist das Vorhandensein einer genetischen Prädisposition. Daneben gibt es Faktoren mit protektiver Wirkung – wie die Einnahme hormoneller Kontrazeptiva mit Ovulationshemmung – sowie gesicherte Risikofaktoren, die mit einer erhöhten Wahrscheinlichkeit, an einem sporadischem Ovarialkarzinom zu erkranken, einhergehen.
 

  • Literatur

  • 1 Jacobs IJ, Menon U, Ryan A. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening. (UKCTOCS): a randomised controlled trial. Lancet 2016; 387: 945-956
    CrossrefPubMedGoogle Scholar
  • 2 Buys SS, Partridge E, Black A. et al. Effect of Screening on Ovarian Cancer Mortality. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011; 305: 2295-2303
    CrossrefPubMedGoogle Scholar
  • 3 Kobayashi H, Yamada Y, Sado T. et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008; 18: 414-420
    CrossrefPubMedGoogle Scholar
  • 4 Leitlinienprogramm Onkologie (DGK, DGGG, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren (Langversion). Version 2.1, Oktober 2017. https://www.ago-online.de/fileadmin/downloads/leitlinien/ovar/2017/032–035-OLl_Ovarialkarzinom_2017–10.pdf
    PubMedGoogle Scholar
  • 5 Robert Koch-Institut. Krebs in Deutschland 2011/2012. 10. ed. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg). Berlin: 2015
    Google Scholar
  • 6 International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. In: Online Analysis 9 Prediction. Lyon, France: IARC (International Agency for Research on Cancer); 2016
    Google Scholar
  • 7 Shih-le M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518
    CrossrefPubMedGoogle Scholar
  • 8 Bell D, Berchuck A, Birrer M. et al. Integrated Genomic Analyses of Ovarian Carcinoma. Nature 2011; 474: 609-615
    CrossrefPubMedGoogle Scholar
  • 9 Meindl A, Hellebrand H, Wiek C. et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nature Genetics 2010; 42: 410-414
    CrossrefPubMedGoogle Scholar
  • 10 Manchanda R, Legood R, Antoniou AC. et al. Setting the treshold for surgical prevention in women at increased risk of ovarian cancer. Int J Gynecol Cancer 2018; 28: 34-42
    CrossrefPubMedGoogle Scholar
  • 11 Loveday C, Turnbull C, Ramsay E. et al.  Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics  2011; 43: 879-882
    CrossrefPubMedGoogle Scholar
  • 12 Pennington KP, Walsh T, Harrell MI. et al. Germline and somatic Mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube and peritoneal carcinomas. Clin Cancer Res 2014; 20: 764-775
    CrossrefPubMedGoogle Scholar
  • 13 Cancer Research UK. Ovarian cancer statistics. London, UK: Cancer Research UK. Available at: 2017 http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer Accessed March 1, 2017
    PubMedGoogle Scholar
  • 14 SEER Cancer Statistics Factsheets: Ovary Cancer. Bethesda, MD: National Cancer Institute. 2014 Available at: http://seer.cancer.gov/statfacts/html/ovary.html Accessed October 3, 2015
    PubMedGoogle Scholar
  • 15 Majdak EJ, Debniak J, Milczek T. et al. Prevalence and clinical correlations of BRCA1 / BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases – preliminary report. Eur J Cancer 2005; 41: 143-150
    CrossrefPubMedGoogle Scholar
  • 16 Alsop K, Fereday S, Meldrum C. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer. A report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654-2663
    CrossrefPubMedGoogle Scholar
  • 17 Mavaddat N, Peock S, Frost D. et al. Cancer risks of BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-822
    CrossrefPubMedGoogle Scholar
  • 18 Malander S, Ridderheim M, Masback A. et al. One in 10 ovarian cancer patients carry germline BRCA1 or BRCA2 mutations. Eur J Cancer 2004; 40: 422-428
    CrossrefPubMedGoogle Scholar
  • 19 Pal T, Permuth-Wey J, Kapoor R. et al. Improved survival in BRCA2 carriers with ovarian cancer. Cancer 2005; 104: 2807-2816
    CrossrefPubMedGoogle Scholar
  • 20 Bolton KL, Chenevix-Trench G, Goh C. et al. Association between BRCA1 und BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012; 307: 382-390
    CrossrefPubMedGoogle Scholar
  • 21 Harter P, Hauke J, Heitz F. et al. Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarial cancer (OC) patients (AGO TR-1). J Clin Oncol; 2016 34. suppl: abstr 5538
    PubMedGoogle Scholar
  • 22 WHO and IARC. Hormonal contraception and post-menopausal hormonal therapy. 72: 19994
    PubMedGoogle Scholar
  • 23 Cibula D, Widschwendter M, Májek O. et al. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011; 17: 55-67
    CrossrefPubMedGoogle Scholar
  • 24 Jordan SJ, Green AC, Whiteman DC. et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer 2008; 122: 1598-1603
    PubMedGoogle Scholar
  • 25 Beral V. et al. Menopausal hormone use and ovarian cancer risk: individual participant metaanalysis of 52 epidemiological studies. Lancet 2015; 385: 1835-1842
    CrossrefPubMedGoogle Scholar
  • 26 Shi LF, Wu Y, Li CY. Hormone therapy and risk of ovarian cancer in postmenopausal. Menopause 2016; 23: 417-424
    PubMedGoogle Scholar
  • 27 Beral V, Gaitskell K, Hermon C. et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369: 1703-1710
    CrossrefPubMedGoogle Scholar
  • 28 Anderson GL. et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 2003; 290: 1739-1748
    CrossrefPubMedGoogle Scholar
  • 29 Morch LS, Lokkegaard E, Andreasen AH. et al. Hormone therapy and ovarian cancer. JAMA 2009; 302: 298-305
    CrossrefPubMedGoogle Scholar
  • 30 Rebbeck TR, Lynch HT, Neuhausen SL. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622
    CrossrefPubMedGoogle Scholar
  • 31 Kauff ND, Satagopan JM, Robson ME. et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615
    CrossrefPubMedGoogle Scholar
  • 32 Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80-87
    CrossrefPubMedGoogle Scholar
  • 33 Finch AP, Lubinski J, Moller P. et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014; 32: 1547-1553
    CrossrefPubMedGoogle Scholar
  • 34 Marchetti C, De Felice F, Palaia I. et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 2014; 14: 150
    CrossrefPubMedGoogle Scholar
  • 35 Polcher M, Hauptmann S, Fotopoulou C. et al. Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO. Arch Gynecol Obstet  2015; 292: 231-234
    CrossrefPubMedGoogle Scholar
  • 36 Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 2002; 346: 1660-1662
    CrossrefPubMedGoogle Scholar
  • 37 Casey MJ, Synder C, Bewtra C. et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005; 97: 457-467
    CrossrefPubMedGoogle Scholar
  • 38 Polcher M, Hauptmann S, Fotopoulou C. et al. Should Fallopian Tubes Be Removed During Hysterectomy Procedures? – A Statement by AGO Ovar. Geburtsh Frauenheilk 2015; 75: 339-341
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 39 Falconer H, Yin L, Gronberg H. et al. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 2015; 107 DOI: 10.1093/jnci/dju410.
    CrossrefPubMedGoogle Scholar
  • 40 Cannioto R, LaMonte MJ. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev  2016; 25: 1114-1124
    CrossrefPubMedGoogle Scholar
  • 41 World Cancer Research Fund / American Institute for Cancer Research. Continuous Update Project Report. Food, Nutrition, Physical Activity, and the Prevention of Ovarian Cancer. Washington DC: 2014
    PubMedGoogle Scholar
  • 42 Leitzmann MF, Koebnick C, Danforth KN. et al. Body mass index and risk of ovarian cancer. Cancer 2009; 115: 812-822
    CrossrefPubMedGoogle Scholar
  • 43 Kiechle M, Engel C, Berling A. et al. Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial. Trials 2016; 17: 368 . doi: 10.1186/s13063–016–1504–0
    CrossrefPubMedGoogle Scholar